Stannsoporfin

DB04912InvestigationalSmall molecule

Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing jaundice.

Mechanism: Kernicterus is attributed to high levels of bilirubin, a by-product of heme metabolism. Bilirubin is a bile pigment, which is normally eliminated from the body after conversion into a water-soluble form by the liver. Stannsoporfin's mechanism of action specifically inhibits the enzyme that blocks the conversion of heme into bilirubin.
Curator reviewed
Primary indication: Investigated for use/treatment in liver disease, metabolic disease, and pediatric indications.Curator reviewed
Formula / weight: C₃₄H₃₆Cl₂N₄O₄Sn · 754.3 g/mol (avg)
Also known as: Tin mesoporphyrin
Code names: B-992

Resolves to

Compound

UNII0KAE1U0G7QCAS106344-20-1PubChem15978579

Structure

InChIKeyLLDZJTIZVZFNCM-UHEVNVKKSA-JSMILES[Cl-].[Cl-].[Sn+4].CCC1=C2[N-]C(\C=C3/N=C(/C=C4\[N-]\C(=C/C5=N/C(=C\2)/C(C)=C5CC)C(C)=C4CCC(O)=O)C(CCC(O)=O)=C3C)=C1C

Targets

P09601HMOX1P30519HMOX2

What you can answer from here — as of February 21, 2021

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

11Clinical trialsPhase, status and sponsor resolved per trial

11+ReferencesStructured and connected to the statements they support

Which drugs share a target with Stannsoporfin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account